1
|
Vergote I, Van Nieuwenhuysen E, Casado A, Laenen A, Lorusso D, Braicu EI, Guerra-Alia E, Zola P, Wimberger P, Debruyne PR, Falcó E, Ferrero A, Muallem MZ, Kerger J, García-Martinez E, Pignata S, Sehouli J, Van Gorp T, Gennigens C, Rubio MJ. Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Gynecol Oncol 2023; 174:80-88. [PMID: 37167896 DOI: 10.1016/j.ygyno.2023.04.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 04/19/2023] [Accepted: 04/29/2023] [Indexed: 05/13/2023]
Abstract
OBJECTIVE Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor. The aim was to establish the role of nintedanib in addition to paclitaxel and carboplatin in first-line recurrent/metastatic cervical cancer. METHODS Double-blind phase II randomized study in patients with first-line recurrent or primary advanced (FIGO stage IVB) cervical cancer. Patients received carboplatin-paclitaxel with oral nintedanib 200 mg BID/placebo. The primary endpoint was progression-free survival (PFS) at 1.5 years and α = 0.15, β = 80%, one sided. RESULTS 120 patients (62 N, 58C) were randomized. Median follow-up was 35 months. Baseline characteristics were similar in both groups (total population: squamous cell carcinoma 62%, prior radiotherapy 64%, primary advanced 25%, recurrent 75%). The primary endpoint was met with a PFS at 1.5 years of 15.1% versus 12.8% in favor of the nintedanib arm (p = 0.057). Median overall survival (OS) was 21.7 and 16.4 months for N and C, respectively. Confirmed RECIST response rate was 48% for N and 39% for C. No new adverse events were noted for N. However, N was associated with numerically more serious adverse events for anemia and febrile neutropenia. Global health status during and at the end of the study was similar in both arms. CONCLUSION The study met its primary endpoint with a prolonged PFS in the N arm. No new safety signals were observed.
Collapse
Affiliation(s)
- I Vergote
- Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and University Hospitals Leuven, Division of Gynaecological Oncology, Leuven, European Union, Belgium.
| | - E Van Nieuwenhuysen
- Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and University Hospitals Leuven, Division of Gynaecological Oncology, Leuven, European Union, Belgium
| | - A Casado
- Hospital Clínico San Carlos, Spain and Grupo Español de Cáncer de Ovario (GEICO), Madrid, Spain
| | - A Laenen
- Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium
| | - D Lorusso
- Multicentre Italian Trials in Ovarian Cancer and Gynecologic malignancies (MITO) and Fondazione Policlinico Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Roma, Italy
| | - E I Braicu
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany; Stanford University, Department of Obstetrics and Gynecology, CA, USA
| | - E Guerra-Alia
- Hospital Universitario Ramón y Cajal, and GEICO, Madrid, Spain
| | - P Zola
- Mario Negri Gynecologic Oncology Group (MaNGO) and Department of Surgical Sciences Università degli Studi di Torino, Italy
| | - P Wimberger
- NOGGO and Technische Universität Dresden and NCT Dresden, Dresden, Germany
| | - P R Debruyne
- BGOG and Kortrijk Cancer Centre, AZ Groeninge, Kortrijk, Belgium; School of Life Sciences, Anglia Ruskin University, Cambridge, UK; School of Nursing & Midwifery, University of Plymouth, Plymouth, UK
| | - E Falcó
- GEICO and Policlinica Miramar, Palma de Mallorca, Spain
| | - A Ferrero
- MaNGO and Mauriziano Hospital and University of Torino, Torino, Italy
| | - M Z Muallem
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany
| | - J Kerger
- BGOG and Instituut Jules Bordet, Brussels, Belgium
| | - E García-Martinez
- Hospital General Universitario Morales Meseguer, Murcia, Spain and GEICO
| | - S Pignata
- MITO and Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Italy
| | - J Sehouli
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, Berlin, Germany
| | - T Van Gorp
- Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and University Hospitals Leuven, Division of Gynaecological Oncology, Leuven, European Union, Belgium
| | | | - M J Rubio
- Hospital Reina Sofía, Córdoba, Spain and GEICO
| |
Collapse
|
2
|
Punsola-Izard V, Schultz KS, Ozaes-Lara E, Mendieta-Zamora J, Romera-Orfila G, Carnicero N, Llusá-Perez M, Casado A. Preliminary study of elastic-tension digital neoprene orthoses for proximal interphalangeal joint flexion contracture. Hand Surg Rehabil 2023; 42:69-74. [PMID: 36336264 DOI: 10.1016/j.hansur.2022.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/11/2022] [Accepted: 10/18/2022] [Indexed: 11/05/2022]
Abstract
Flexion contracture of the proximal interphalangeal joint (PIPJ) is one of the most frequent complications in finger trauma. Orthoses are the most widely used method to optimize total end-range time (TERT). No previous studies showed that an elastic tension orthosis could be applied for longer than 12 h. We aimed to demonstrate that the elastic-tension digital neoprene orthosis (ETDNO) can achieve higher TERT and therefore better range of motion than other elastic-tension orthoses (ETO) described in the literature. A prospective study of treatment of PIPJ flexion contracture included 10 PIP joints in 8 patients who met the selection criteria. They were instructed to use the ETDNO for around 23 h per day as far as possible, during a period of 3 weeks. Patients reported a mean TERT of 20.6 h a day. PIPJ contracture improved by a mean Torque Range of Motion (TROM) of 23.5° at 500 g and 22.9° at 800 g of passive extension force during the 3-week treatment. Based on the results of this study, the ETDNO appears to offer a highly effective approach for improving PIPJ flexion contracture, increasing range of motion in extension. ETDNO's efficacy probably lies in the significantly improved comfort and low-profile design, enabling excellent compliance and thus optimizing TERT. LEVEL OF EVIDENCE: Level III.
Collapse
Affiliation(s)
- V Punsola-Izard
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain; Unit of Human Anatomy and Embryology, University of Barcelona, C/Casanova 143, 08036 Barcelona, Spain; Gimbernat School of Physical Therapy, Avinguda de la Generalitat s/n, 08174 Sant Cugat del Vallès, Spain.
| | - K S Schultz
- Senior Consulting Therapist: Karen Schultz Hand and Upper Limb Strategies (KSHULS), Spain
| | - E Ozaes-Lara
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain
| | - J Mendieta-Zamora
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain; Gimbernat School of Physical Therapy, Avinguda de la Generalitat s/n, 08174 Sant Cugat del Vallès, Spain
| | - G Romera-Orfila
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain
| | - N Carnicero
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain
| | - M Llusá-Perez
- Unit of Human Anatomy and Embryology, University of Barcelona, C/Casanova 143, 08036 Barcelona, Spain
| | - A Casado
- Hand Therapy Barcelona, C/Roger de Lluria 5, 08010 Barcelona, Spain; Unit of Human Anatomy and Embryology, University of Barcelona, C/Casanova 143, 08036 Barcelona, Spain; Gimbernat School of Physical Therapy, Avinguda de la Generalitat s/n, 08174 Sant Cugat del Vallès, Spain
| |
Collapse
|
3
|
Cardoso L, Pena S, Gómez L, Del Castillo Á, Del Valle M, Gutiérrez J, Herrera M, Garavis M, Casado A, Valencia P, Jaraíz R, Hurtado A, Alonso P, Solis I, Conles I, Rodríguez D, Sánchez M, Diezhandino P. PO-1092 Clinical implication of different treatment techniques in glottic cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03056-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Cardoso L, Del Valle M, Gómez L, Pena S, Sanz Á, Garavís M, Herrera M, Gutiérrez J, Valencia P, Casado A, Jaraíz R, Hurtado E, Alonso P, Rodríguez D, Sánchez M, Solís I, Diezhandino P. PO-1180 Incidental vs elective irradiation of internal mammary chain. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03144-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Camacho AI, Mas-Peinado P, Hutchins BT, Schwartz BF, Dorda BA, Casado A, Rey I. New stygofauna from Texas, USA: three new species of Parabathynellidae (Crustacea: Bathynellacea). J NAT HIST 2021. [DOI: 10.1080/00222933.2021.1928316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- A. I. Camacho
- Dpto. Biodiversidad y Biología Evolutiva, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
| | - P. Mas-Peinado
- Dpto. Biodiversidad y Biología Evolutiva, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
- Centro de Investigación en Biodiversidad y Cambio Global CIBC-UAM, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid, Spain
| | - B. T. Hutchins
- Edwards Aquifer Research and Data Center, Texas State University, San Marcos, TX, USA
| | - B. F. Schwartz
- Edwards Aquifer Research and Data Center, Texas State University, San Marcos, TX, USA
- Department of Biology, Texas State University, San Marcos, TX, USA
| | - B. A. Dorda
- Dpto. Colecciones, Colección de Tejidos y AND, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
| | - A. Casado
- Dpto. Colecciones, Colección de Tejidos y AND, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
| | - I. Rey
- Dpto. Colecciones, Colección de Tejidos y AND, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
| |
Collapse
|
6
|
Cardoso L, Del Valle M, Gómez L, Pena S, Del Castillo Á, Casado A, Valencia P, Garavis M, Herrera M, Alonso P, Martín M, Sanz Á, Rodríguez D, Diezhandino P. PO-1117 Incidental irradiation of the internal mammary in breast radiotherapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07568-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Cerveró A, González Bores P, Casado A, Ruiz Sancho MD, Hernández Hernández JL, Napal Lecumberri JJ. Retinal vein occlusion in solid organ transplant recipients. Study of 4 cases and literature review. Arch Soc Esp Oftalmol (Engl Ed) 2020; 95:615-618. [PMID: 32197874 DOI: 10.1016/j.oftal.2020.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 02/08/2020] [Accepted: 02/11/2020] [Indexed: 06/10/2023]
Abstract
Although retinal venous obstruction (RVO) has been primarily related to vascular risk factors and glaucoma, there are a few studies of RVO in patients with solid organ transplants. An analysis was performed on total of 331 patients who presented with RVO (branch RVO in 226 cases and central RVO in 105 cases) over a 10 year period, and the characteristics were compared with the 4 patients with a history of solid organ transplant (liver, renal, or bipulmonary) who presented with RVO. In this series, the onset of RVO in transplant patients occurred at earlier ages than in other patients with RVO (58 vs. 68 years, respectively), affected the central vein of the retina (100% vs. 32%), and was associated with diabetes mellitus (75% vs. 25%), as well as with steroidal (100% vs. 1%) and immunosuppressive (tacrolimus 75% vs. 0%) treatments.
Collapse
Affiliation(s)
- A Cerveró
- Servicio de Oftalmología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España.
| | - P González Bores
- Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España
| | - A Casado
- Servicio de Oftalmología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España
| | - M D Ruiz Sancho
- Servicio de Oftalmología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España
| | - J L Hernández Hernández
- Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España; Universidad de Cantabria, Santander, España
| | - J J Napal Lecumberri
- Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, España
| |
Collapse
|
8
|
Castañeda S, Vicente E, Llamas Velasco M, Sanchez Perez J, Pardo J, Cabeza-Martínez R, Miranda-Fontes M, Márquez J, Calvo J, Armesto S, Belinchón I, Gómez A, Miranda MD, Martinez Pardo S, Merino-Meléndez L, Casado MA, Yébenes M, Casado A. OP0262-HPR COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS. COEPSO STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and both diseases (PsA+Ps) is an important subject as they are associated with a substantial economic impact, with implications from a health management perspective.Objectives:To describe the economic burden of direct non-healthcare and indirect resources of patients with Ps, PsA and PsA+Ps in Spain.Methods:COEPSO (“Evaluation of Costs in patients with Psoriatic Disease”) was an observational, retrospective, cross-sectional study performed in 22 Spanish centers (17 Dermatology and 14 Rheumatology Services), from February 2017 to February 2018, including moderate to severe Ps and PsA patients (with or without Ps), naive to biologics. Direct non-healthcare (social services, home care, physical adaptations, private health and non-health professionals, non-reimbursed and non-pharmaceutical therapies), indirect (loss of productivity) and total costs (direct non-healthcare and indirect costs) related to the disease during the previous year to the study were obtained. Unitary costs (€, 2018) were calculated: out-of-pocket costs were specified directly by patients and loss of productivity costs by means of average salaries based on occupation specified by patients. The information was collected through a case report form filled out by the investigators and a telephone survey administered to the patients.Results:A total of 318 patients were included (196 Ps; 43 PsA and 79 PsA+Ps), mean age 48.7 years and 51.3% males. Metabolic syndrome was the most frequent comorbidity in all groups. The average annual total cost per patient was 1,042.71€ (SD 3,817.55), 1,137.84€ (SD 3,070.39) and 1,830.26€ (SD 5,835.81) for Ps, PsA and PsA+Ps, respectively. The average annual direct non-healthcare cost per patient was 749.57€ (SD 2,393.77), 750.50€ (SD 1,641.82) and 1,247.56€ (SD 4,467.19) for Ps, PsA and PsA+Ps, respectively. The average annual indirect cost per patient was 293.14€ (SD 2,855.27), 387.35€ (SD 2,409.63) and 582.71€ (SD 3,842.12) for Ps, PsA and PsA+Ps, respectively.Patients with combined PsA+Ps had higher annual total cost (direct non-healthcare and indirect costs) than patients with only one of these manifestations separately (75.5% and 60.9% above patients with Ps and PsA, respectively). Total costs in patients with Ps and PsA were similar. Direct non-healthcare costs represent between 66.0% (patients with PsA) to 71.9% (patients with Ps) of total cost. Indirect costs represent between 28.1% (patients with Ps) to 34.0% (patients with PsA) of total cost.Conclusion:PsA and Ps have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs. Moreover, although annual total costs in patients with PsA were similar to those of Ps patients, the combination of both manifestations yielded the highest costs suggesting the importance of the increased disease load.Disclosure of Interests:Santos Castañeda: None declared, Esther Vicente Speakers bureau: BMS, Roche., Mar Llamas Velasco: None declared, Javier Sanchez Perez: None declared, José Pardo: None declared, Rita Cabeza-Martínez: None declared, Mercedes Miranda-Fontes: None declared, Juan Márquez: None declared, Jaime Calvo Grant/research support from: Lilly, UCB, Consultant of: Abbvie, Jansen, Celgene, susana armesto: None declared, Isabel Belinchón: None declared, Alejandro Gómez: None declared, María Dolores Miranda: None declared, Silvia Martinez Pardo: None declared, Leticia Merino-Meléndez: None declared, Miguel Angel Casado Consultant of: UCB Pharma, María Yébenes: None declared, Araceli Casado: None declared
Collapse
|
9
|
Cerveró A, López-de-Eguileta A, Cano-Abascal Á, Sedano-Tous MJ, Drake-Pérez M, Casado A. Anisocoria as initial manifestation of multiple sclerosis. Use of 3 tesla magnetic resonance imaging. Arch Soc Esp Oftalmol (Engl Ed) 2020; 95:192-195. [PMID: 32147131 DOI: 10.1016/j.oftal.2020.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 12/29/2019] [Accepted: 01/03/2020] [Indexed: 06/10/2023]
Abstract
A 21-year-old woman seen in this clinic with non-reactive mydriasis in the right eye that contracted with 1% pilocarpine. Cranial angio-CT and 1.5 T magnetic resonance imaging (MRI) did not detect any disease. Given a subsequent limitation of adduction, supraduction, and infarction of the right eye, a 3 T MRI was requested. This showed a lesion of the midbrain at the exit of the 3rd cranial nerve. After improvement, no new episodes were observed until 18 months later, when the patient presented with probable optic neuritis and systemic symptoms. At this time the 1.5 T MRI detected infratentorial and supratentorial demyelinating plaques. A subsequent lumbar puncture and clinic outcome confirmed the diagnosis of relapsing-remitting multiple sclerosis.
Collapse
Affiliation(s)
- A Cerveró
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España.
| | - A López-de-Eguileta
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - Á Cano-Abascal
- Departamento de Neurología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - M J Sedano-Tous
- Departamento de Neurología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - M Drake-Pérez
- Departamento de Radiología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - A Casado
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| |
Collapse
|
10
|
Cerveró A, Sedano-Tous MJ, Madera J, López-de-Eguileta A, Casado A. Use of ganglion cell layer analysis for diagnosing anti-glycoprotein neuromyelitis optica of oligodendrocyte myelin. ACTA ACUST UNITED AC 2020; 95:146-149. [PMID: 31980323 DOI: 10.1016/j.oftal.2019.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 11/20/2019] [Accepted: 11/24/2019] [Indexed: 10/25/2022]
Abstract
The case concerns a 26-year-old patient with bilateral recurrent optic neuritis episodes in the context of suspected neuromyelitis optica. In the first outbreak, she had greatly impaired visual acuity of the left eye, as well as seeing ganglion cell layer damage in both eyes in the optic coherence tomography, with evidence of a possible extensive lesion in the optic chiasma. Likewise, MRI with contrast showed a great involvement of the left optic nerve that compromises the chiasma increasing the suspicion of a neuromyelitis origin. Althogh the anti-myelin oligodendrocyte glycoprotein (MOG) and anti-AQP4 (aquaporin-4) antibodies were negative at first, bilateral involvement of the ganglion cells suggested an extensive lesion that is more characteristic of seropositive anti-MOG neuromyelitis.
Collapse
Affiliation(s)
- A Cerveró
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - M J Sedano-Tous
- Departamento de Neurología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - J Madera
- Departamento de Neurología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - A López-de-Eguileta
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España
| | - A Casado
- Departamento de Oftalmología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, España.
| |
Collapse
|
11
|
Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol 2019; 29:910-916. [PMID: 29415128 DOI: 10.1093/annonc/mdy037] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Backround The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment. Patients and methods A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version. Results From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included. Conclusion This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.
Collapse
Affiliation(s)
- G Oskay-Özcelik
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - S Alavi
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - R Richter
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin
| | - M Keller
- North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - R Chekerov
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - S C Cecere
- Division of Medical Oncolog, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - G Cormio
- Department of Biomedical Science and Human Oncolog, Obstetrics and Gynecology Unit, University of Bari, Bari, Italy
| | - F Joly
- Department of Medical Oncolog, Centre Francois Baclesse, Universite Basse Normandie, Caen, France
| | - J E Kurtz
- Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - A du Bois
- Deptartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany
| | - M Maciejewski
- Dolnoslaskie Centrum onkologii/Oddzial Ginekologii Onkologicznej, Wroclaw, Poland
| | - M Jedryka
- Department of Oncology and Gynaecological Oncology Clinic, Wroclaw Medical University, Wroclaw, Poland
| | - I Vergote
- Division of Gynaecological Oncol, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
| | - E Van Nieuwenhuysen
- Division of Gynaecological Oncol, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
| | - A Casado
- Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - C Mendiola
- University Hospital 12 de Octubre, Madrid, Spain
| | - P Achimas-Cadariu
- Department of Surgery, The Oncology Institute Ion Chiricuţă, Cluj-Napoca, Romania; Department of Surgery and Gynecologic Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - C Vlad
- Department of Surgery, The Oncology Institute Ion Chiricuţă, Cluj-Napoca, Romania; Department of Surgery and Gynecologic Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - D Reimer
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - A G Zeimet
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Friedlander
- Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
| | - J Sehouli
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany.
| |
Collapse
|
12
|
Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, Sepúlveda MA, Salgado X, Rodriguez M, Santos J, Yzusqui M, Mayorga MI, Lorenzo JF, Bahamonde A, Bachiller P, Martínez E, Rozas N, Torres C, Muñoz A, Casado A, Podzamczer D. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. J Antimicrob Chemother 2019; 73:2171-2176. [PMID: 29788066 DOI: 10.1093/jac/dky175] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 04/16/2018] [Indexed: 01/15/2023] Open
Abstract
Objectives To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral regimens to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) in a real-world setting. Methods PRO-STR is a 48 week prospective observational post-authorization study in 25 hospitals. Patients with a viral load <1000 copies/mL, receiving at least 12 months of combination ART (cART), with constant posology for at least the prior 3 months, were categorized according to previous treatment [NNRTI or ritonavir-boosted PI (PI/r)]. Analytical tests were performed at the baseline visit, between week 16 and week 32, and at week 48. Results A total of 303 patients were included (mean age 46.6 years; male 74.0%; previous treatment 74.7% NNRTI and 25.3% PI/r). Both groups exhibited significantly reduced lipid profiles, except for HDL cholesterol, for which a non-significant increase was observed. [NNRTI patients: total cholesterol (baseline: 195.5 ± 38.4 mg/dL; week 48: 171.0 ± 35.5 mg/dL), total cholesterol/HDL ratio (baseline: 4.2 ± 1.2; week 48: 4.0 ± 1.2), HDL (baseline: 49.1 ± 12.0 mg/dL; week 48: 49.2 ± 45.8 mg/dL), LDL (baseline: 119.2 ± 30.2 mg/dL; week 48: 114.2 ± 110.7 mg/dL), and triglycerides (baseline: 136.6 ± 86.8 mg/dL; week 48: 113.4 ± 67.8 mg/dL); PI/r patients: total cholesterol (baseline: 203.2 ± 48.8 mg/dL; week 48: 173.4 ± 36.9 mg/dL), total cholesterol/HDL ratio (baseline: 4.7 ± 1.6; week 48: 4.0 ± 1.2), HDL (baseline: 46.4 ± 12.5 mg/dL; week 48: 52.1 ± 54.4 mg/dL), LDL (baseline: 127.0 ± 36.3 mg/dL; week 48: 111.4 ± 35.8 mg/dL), and triglycerides (baseline: 167.6 ± 107.7 mg/dL; week 48: 122.7 ± 72.1 mg/dL)]. The most common intolerances were neuropsychiatric in the NNRTI patients and gastrointestinal and metabolic in the PI/r patients, and these intolerances were significantly reduced in both groups at week 48 [NNRTI: neuropsychiatric (baseline: 81.3%; week 48: 0.0%); PI/r: gastrointestinal (baseline: 48.7%; week 48: 0.0%) and metabolic (baseline: 42.1%; week 48: 0.0%)]. Conclusions RPV/FTC/TDF improved the lipid profiles and reduced the intolerances after switching from NNRTI or PI-based regimens, in a cohort of HIV-infected patients.
Collapse
Affiliation(s)
- A Ocampo
- Xeral de Vigo Hospital, Pontevedra, Spain
| | - P Domingo
- de la Santa Creu y Sant Pau Hospital, Barcelona, Spain
| | | | - J Diz
- de Montecelo Hospital, A Coruña, Spain
| | - J R Barberá
- La Mancha Centro Hospital, Ciudad Real, Spain
| | | | - X Salgado
- University de Girona Dr Josep Trueta Hospital, Girona, Spain
| | | | - J Santos
- Virgen de la Victoria Hospital, Málaga, Spain
| | - M Yzusqui
- Nuestra Señora del Prado Hospital, Toledo, Spain
| | | | | | | | - P Bachiller
- University del Río Hortega Hospital, Valladolid, Spain
| | - E Martínez
- University de Albacete Hospital, Albacete, Spain
| | - N Rozas
- University de Bellvitge, Barcelona Hospital, Barcelona, Spain
| | - C Torres
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - A Muñoz
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - A Casado
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - D Podzamczer
- University de Bellvitge, Barcelona Hospital, Barcelona, Spain
| |
Collapse
|
13
|
Tamargo Delpon MA, Gutierrez E, Diez-Delhoyo F, Gonzalez-Saldivar H, Rivera AR, Casado A, Vazquez ME, Sanz R, Soriano J, Elizaga J, Fernandez-Aviles FJ. P5621Diagnostic accuracy of resting full-cycle ratio in the non-culprit artery of acute patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0565] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Resting full-cycle ratio (RFR) is a novel non-hyperemic index of coronary stenosis severity, independent of the timing within the cardiac cycle. Recent data has demonstrated good correlation between RFR and Fractional Flow Reserve (FFR) in stable coronary disease (SCD). However, there are no data regarding the reliability of RFR in non-culprit arteries of patients presenting with acute myocardial infarction (AMI).
Purpose
To study the diagnostic accuracy of RFR versus FFR in the non-culprit artery in AMI compared to stable lesions.
Methods
RFR, FFR, Coronary Flow Reserve (CFR), Index of Microcirculatory Resistance (IMR), and Resistance Reserve Ratio (RRR) were calculated in 67 patients with AMI and an intermediate lesion in a non-culprit artery (median time from primary PCI to study: 48 hours). Data were compared with those of a retrospective group of 66 patients with SCD.
Results
There was a higher proportion of males among patients of the AMI group (85% vs 62%, p=0.0026). Mean age was 64.5±11 years, being AMI cohort younger at presentation [62±11 vs 67±12 years in SCD cohort (p=0.04)]. Patients with AMI had a significantly lower prevalence of hypertension (52% vs 75%, p=0.006), diabetes (10% vs 32%), p=0.002) and hyperlipemia (37% vs 79%, p=0.002).
Coronary physiology parameters showed a non-normal distribution, and are expressed as median [IQR] (Table 1). In patients with AMI, FFR was lower than in patients with SCD. In contrast, RFR showed no significant difference. Both CFR and RRR were higher in the AMI group. No significant differences in IMR were found between cohorts.
Importantly, in the AMI group the correlation between RFR and FFR was 0.84 and the overall agreement 82%, with rates of false positive and negative of 15% and 3%, respectively. In SCD the correlation was 0.81 with a lower overall agreement of 69%, due mostly to a higher rate of false positive RFR (28%) (Figure 1).
Table 1. Microcirculatory parameters in non-culprit artery (AMI) and stable coronary disease (SCD) AMI (N=66) Stable (N=67) p value FFR 0.84 [0.76–0.9] 0.84 [0.76–0.9] 0.006 RFR 0.89 [0.82–0.94] 0,9 [0.84–0.94] 0.24 CFR 2.2 [1.7–3.1] 1.8 [1.1–2.6] 0.011 IMR 17 [14–27] 25 [14–38] 0.051 RRR 2.7 [2.17 - 3.9] 2.1 [1.4–3.1] 0.005 Median [IQR].
Figure 1. Correlation between RFR and FFR valueS
Conclusions
RFR shows a good correlation with FFR in AMI. Surprisingly, overall agreement is higher in the non-culprit artery in an acute setting, with a lower percentage of false positive results.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
| | - E Gutierrez
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - F Diez-Delhoyo
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | | | - A R Rivera
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - A Casado
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - M E Vazquez
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - R Sanz
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - J Soriano
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - J Elizaga
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | | |
Collapse
|
14
|
Tamargo Delpon MA, Gutierrez Ibanes E, Diez-Delhoyo F, Gonzalez-Saldivar H, Rivera AR, Casado A, Vazquez ME, Sanz R, Soriano J, Elizaga J, Fernandez-Aviles FJ. 6115Influence of microvascular function and coronary flow in the diagnostic precision of resting full-cycle ratio. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Introduction
Resting full-cycle ratio (RFR) has been recently described as a non-hyperemic index of coronary stenosis with good concordance with Fractional Flow Reserve (FFR). However, there is no information concerning the influence of microvascular function and coronary flow on RFR results.
Purpose
To determine if the accuracy of this novel parameter might be influenced by changes in microvascular function.
Methods
133 patients admitted in our center between July 2016 and December 2017 underwent coronary physiology study of an angiographically intermediate lesion. 67 subjects presented with AMI and an intermediate lesion in a non-culprit artery, and 66 subjects stable coronary disease. We performed FFR, Coronary Flow Reserve (CFR), Index of Microcirculatory Resistance (IMR) and Resistance Reserve Ratio (RRR) in all of them. We calculated RFR retrospectively from the pressure tracings.
Results
Coronary physiology parameters showed a non-normal distribution and are presented as median [IQR]: FFR 0.86 [0.79–0.92]; CFR 2.05 [1.4–2.95]; IMR 20.5 [14–32.55]; RRR 2.5 [1.85–3.63]; RFR 0.897 [0.83–0.94]. Patients with abnormal CFR displayed lower RFR values although FFR was not markedly affected (Table 1). These findings remained irrespective of the clinical scenario at presentation.
61 patients had a CFR lower than 2. Correlation between RFR and FFR was not significantly different in patients with abnormal CFR than in those with normal CFR (0,73 vs 0,88; p=0,067) (Figure 1); however, overall binary agreement between RFR and FFR was worse in patients with a low CFR (69% vs 83%; p=0,047).
48 patients had a high IMR (>25). Linear correlation between RFR and FFR was similar in patients with high and normal IMR (0,81 vs 0,83; p=0,784); likewise, binary concordance showed no significant difference between both groups (77% vs 75%, p=0,78).
The mean difference between RFR and FFR was 0,025. This was only influenced by CFR: patients with a low CFR had a smaller difference than those with a normal CFR (0,012 vs 0,035; p=0,019).
Physiology parameters by CFR group Normal CFR (≥2) Low CFR (<2) P-value FFR 0.88 [0.82–0.93] 0.84 [0.79–0.92] 0.14 RFR 0.91 [0.88–0.95] 0.86 [0.80–0.92] 0.0009 IMR 16.5 [13–27] 25 [16–45.5] 0.002 RRR 3.6 [2.7–4.9] 1.7 [1.3–2.1] <0.0001 Physiological coronary parameters (Median [IQR]) according to CFR.
Correlation between RFR and FFR by CFR
Conclusion
RFR has good overall correlation and concordance with FFR. However, RFR has a lower diagnostic accuracy in patients with a low CFR.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
| | | | - F Diez-Delhoyo
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | | | - A R Rivera
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - A Casado
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - M E Vazquez
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - R Sanz
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - J Soriano
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - J Elizaga
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | | |
Collapse
|
15
|
Podzamczer D, Rozas N, Domingo P, Miralles C, den Eynde EV, Romero A, Deig E, Knobel H, Pasquau J, Antela A, Clotet B, Geijo P, de Castro ER, Casado MA, Muñoz A, Casado A, For The Pro-Str Study Group. Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study. Curr HIV Res 2019; 16:425-435. [PMID: 30760189 PMCID: PMC6700757 DOI: 10.2174/1570162x17666190212163518] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 02/07/2019] [Accepted: 02/11/2019] [Indexed: 12/29/2022]
Abstract
Background: To investigate the impact of switching from stable Combined Antiretroviral Therapy (cART) to single-tablet regimen (RPV/FTC/TDF=EVIPLERA®/COMPLERA®) on patient-reported outcomes in HIV-infected adults who cannot tolerate previous cART, in a real-world setting. Methods: PRO-STR is a 48-week observational, prospective, multicenter study. Presence and magnitude of symptoms (main endpoint), health-related quality-of-life (HRQoL), adherence, satisfaction with treatment and patient preferences were assessed. Results: Three hundred patients with 48-week follow-up, who switched to EVIPLERA® (mean age: 46.6 years; male: 74.0%; 74.7% switched from a non-nucleoside reverse-transcriptase-inhibitor, 25.3% from a protease inhibitor + ritonavir) were included. There was no statistical difference in median CD4+ cell count (baseline: 678.5 cells/mm3; 48-week: 683.0 cells/mm3) neither in virological suppression (≤50 copies/mL) (baseline: 98.3%; 48-week: 95.3%). The most frequent reasons for switching were neuropsychiatric (62.3%), gastrointestinal (19.3%) and biochemical/metabolic (19.3%) events. Only 7.7% of patients permanently discontinued therapy. At 48-week, all outcomes showed an improvement compared to baseline. Overall, there was a significant decrease (p-value≤0.05) in number and magnitude of symptoms, while HRQoL, satisfaction and adherence improved significantly. Most patients prefered EVIPLERA® than previous cART. According to the type of intolerance, HRQoL was improved, but only significantly in patients with neuropsychiatric and gastrointestinal symptoms. Adherence improved significantly in patients with metabolic disturbances and satisfaction with EVIPLERA® was higher in the three groups. Conclusion: Switching to EVIPLERA® from non-nucleoside reverse-transcriptase-inhibitor or protease inhibitor-based regimens due to toxicity, improved the presence/magnitude of symptoms, HRQoL, and preference with treatment. EVIPLERA® maintained a virological response, CD4+ cell count and maintained or improved adherence.
Collapse
Affiliation(s)
- D Podzamczer
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - N Rozas
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - P Domingo
- Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
| | - C Miralles
- Hospital Xeral de Vigo, Pontevedra, Spain
| | | | - A Romero
- Hospital de Especialidades de Puerto Real, Cadiz, Spain
| | - E Deig
- Hospital General de Granollers, Barcelona, Spain
| | - H Knobel
- Hospital del Mar, Barcelona, Spain
| | - J Pasquau
- Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - A Antela
- Complejo Hospitalario Universitario de Santiago, A Coruna, Spain
| | - B Clotet
- Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | - P Geijo
- Hospital Virgen de la Luz, Cuenca, Spain
| | | | - M A Casado
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - A Muñoz
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | - A Casado
- Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
| | | |
Collapse
|
16
|
Martín M, de la Torre-Montero JC, López-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, González Del Val R, Del Monte-Millan M, Massarrah T, Vila C, García-Paredes B, García-Sáenz JA, Lluch A. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat 2018; 171:627-634. [PMID: 29923063 PMCID: PMC6133184 DOI: 10.1007/s10549-018-4855-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 06/13/2018] [Indexed: 11/29/2022]
Abstract
Background Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. Patients and methods BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1.5 to 5 years following primary diagnosis searching for PA. A confirmatory prevalence study was later performed in other two institutions. Finally, a prevention study using prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps in patients receiving adjuvant docetaxel was performed. Results In the initial prevalence study (492 patients), minor forms of PA (grade 1) were recorded with all chemotherapy regimens and aromatase inhibitors. Patients receiving docetaxel regimens at cumulative dose (CD) ≥ 400 mmg/m2 presented a significantly higher prevalence of grades 1 PA (33–52%) and 2 PA (5–12%). Prevalence of grade 2 PA with docetaxel CD ≥ 400 mmg/m2 was confirmed in two other institutions. Overall, grade 2 PA was seen in 10.06% (95% CI 7.36–13.61) of 358 patients with docetaxel regimens reaching CD ≥ 400 mmg/m2, but not in patients with lower docetaxel CD, other chemotherapy regimens, or endocrine therapy alone. In prevention trial, no grade 2 PA occurred among 116 patients receiving adjuvant docetaxel (≥ 400 mmg/m2) and PSC followed-up after a 96 months median time. PSC was well tolerated. No scalp relapses were seen among 30 patients (22% of all inclusions) having disease relapse. Conclusion Adjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762. Electronic supplementary material The online version of this article (10.1007/s10549-018-4855-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M Martín
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain. .,Hospital General Universitario Gregorio Marañón, Medical Oncology Service, Calle Maiquez, no. 9, 28007, Madrid, Spain.
| | - J C de la Torre-Montero
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.,Universidad Pontificia Comillas, Madrid, Spain
| | - S López-Tarruella
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - K Pinilla
- Medical Oncology Department, Hospital Clínico Universitario, CIBERONC, Valencia, Spain
| | - A Casado
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - S Fernandez
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.,Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - Y Jerez
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - J Puente
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - I Palomero
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - R González Del Val
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - M Del Monte-Millan
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - T Massarrah
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - C Vila
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - B García-Paredes
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - J A García-Sáenz
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - A Lluch
- Medical Oncology Department, Hospital Clínico Universitario, CIBERONC, Valencia, Spain
| |
Collapse
|
17
|
Potau JM, Casado A, de Diego M, Ciurana N, Arias-Martorell J, Bello-Hellegouarch G, Barbosa M, de Paz FJ, Pastor JF, Pérez-Pérez A. Structural and molecular study of the supraspinatus muscle of modern humans (Homo sapiens) and common chimpanzees (Pan troglodytes). Am J Phys Anthropol 2018; 166:934-940. [PMID: 29681126 DOI: 10.1002/ajpa.23490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 03/16/2018] [Accepted: 04/05/2018] [Indexed: 11/11/2022]
Abstract
OBJECTIVES To analyze the muscle architecture and the expression pattern of the myosin heavy chain (MyHC) isoforms in the supraspinatus of Pan troglodytes and Homo sapiens in order to identify differences related to their different types of locomotion. MATERIALS AND METHODS We have analyzed nine supraspinatus muscles of Pan troglodytes and ten of Homo sapiens. For each sample, we have recorded the muscle fascicle length (MFL), the pennation angle, and the physiological cross-sectional area (PCSA). In the same samples, by real-time quantitative polymerase chain reaction, we have assessed the percentages of expression of the MyHC-I, MyHC-IIa, and MyHC-IIx isoforms. RESULTS The mean MFL of the supraspinatus was longer (p = 0.001) and the PCSA was lower (p < 0.001) in Homo sapiens than in Pan troglodytes. Although the percentage of expression of MyHC-IIa was lower in Homo sapiens than in Pan troglodytes (p = 0.035), the combination of MyHC-IIa and MyHC-IIx was expressed at a similar percentage in the two species. DISCUSSION The longer MFL in the human supraspinatus is associated with a faster contractile velocity, which reflects the primary function of the upper limbs in Homo sapiens-the precise manipulation of objects-an adaptation to bipedal locomotion. In contrast, the larger PCSA in Pan troglodytes is related to the important role of the supraspinatus in stabilizing the glenohumeral joint during the support phase of knuckle-walking. These functional differences of the supraspinatus in the two species are not reflected in differences in the expression of the MyHC isoforms.
Collapse
Affiliation(s)
- J M Potau
- Unit of Human Anatomy and Embryology, University of Barcelona, Barcelona 08036, Spain
| | - A Casado
- Unit of Human Anatomy and Embryology, University of Barcelona, Barcelona 08036, Spain
| | - M de Diego
- Unit of Human Anatomy and Embryology, University of Barcelona, Barcelona 08036, Spain
| | - N Ciurana
- Unit of Human Anatomy and Embryology, University of Barcelona, Barcelona 08036, Spain
| | - J Arias-Martorell
- Animal Postcranial Evolution (APE) Lab, Skeletal Biology Research Centre, School of Anthropology and Conservation, University of Kent, Canterbury, CT2 7NR, United Kingdom
| | - G Bello-Hellegouarch
- Department of Biology, FFCLRP, University of São Paulo, Ribeirão Preto, São Paulo 3900, Brazil
| | - M Barbosa
- Department of Anatomy and Radiology, University of Valladolid, Valladolid 47005, Spain
| | - F J de Paz
- Department of Anatomy and Radiology, University of Valladolid, Valladolid 47005, Spain
| | - J F Pastor
- Department of Anatomy and Radiology, University of Valladolid, Valladolid 47005, Spain
| | - A Pérez-Pérez
- Department of Evolutionary Biology, Ecology and Environmental Sciences, Section of Zoology and Biological Anthropology, University of Barcelona, Barcelona 08028, Spain
| |
Collapse
|
18
|
Nieto Y, Alonso JL, Ayala F, Ortega L, Casado A, Martín M, Díaz-Rubio E. End-Stage Acute Hepatic Failure as Clinical Presentation of Liver Metastases from Breast Cancer. Tumori 2018; 84:616-7. [PMID: 9862530 DOI: 10.1177/030089169808400523] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A most unusual case of fatal acute hepatic failure as clinical presentation of liver metastases from breast cancer is described. The patient had a four-year history of indolent breast neoplasm and no previously known liver disease.
Collapse
Affiliation(s)
- Y Nieto
- Medical Oncology Department, Hospital Universitario San Carlos, Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
19
|
Poveda A, Del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Guerra Alía EM, Casado A, Gonzalez-Martin A, Fernández C, Rodriguez I, Soto A, Kahatt C, Fernández Teruel C, Galmarini CM, Pérez de la Haza A, Bohan P, Berton-Rigaud D. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol 2018; 28:1280-1287. [PMID: 28368437 PMCID: PMC5452066 DOI: 10.1093/annonc/mdx111] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. Patients and methods Patients with platinum-resistant/refractory ovarian cancer were included in a two-stage, controlled, randomized (in a second stage), multicenter, phase II study. Primary endpoint was overall response rate (ORR) by RECIST and/or GCIG criteria. The exploratory first stage (n = 22) confirmed the activity of PM01183 as a single agent at 7.0 mg flat dose every 3 weeks (q3wk). The second stage (n = 59) was randomized and controlled with topotecan on days 1-5 q3wk or weekly (every 4 weeks, q4wk). Results ORR was 23% (95% CI, 13%-37%) for 52 PM01183-treated patients. Median duration of response was 4.6 months (95% CI, 2.5-6.9 months), and 23% (95% CI, 0%-51%) of responses lasted 6 months or more. Ten of the 12 confirmed responses were reported for 33 patients with platinum-resistant disease [ORR = 30% (95% CI, 16%-49%)]; for the 29 patients treated with topotecan in the second stage, no responses were found. Median PFS for all PM01183-treated patients was 4.0 months (95% CI, 2.7-5.6 months), and 5.0 months (95% CI, 2.7-6.9 months) for patients with platinum-resistant disease. Grade 3/4 neutropenia in 85% of patients; febrile neutropenia in 21% and fatigue (grade 3 in 35%) were the principal safety findings for PM01183. Conclusion PM01183 is an active drug in platinum-resistant/refractory ovarian cancer and warrants further development. The highest activity was observed in platinum-resistant disease. Its safety profile indicates the dose should be adjusted to body surface area (mg/m2). Trial code EudraCT 2011-002172-16.
Collapse
Affiliation(s)
- A Poveda
- Department of Gynecologic Oncology, Instituto Valenciano de Oncología, Valencia
| | - J M Del Campo
- Department of Medical Oncology, Hospital Vall d'Hebrón, Barcelona, Spain
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard and University Claude Bernard, GINECO Group, Lyon
| | - J Alexandre
- Department of Medical Oncology, Paris Descartes University, GH Cochin Hôtel Dieu, Paris
| | - M Provansal
- Department of Medical Oncology, Institut Paoli Calmettes Marseille, France
| | - E M Guerra Alía
- Department of Medical Oncology, Hospital Ramón y Cajal, Madrid
| | - A Casado
- Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid
| | | | - C Fernández
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - I Rodriguez
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - A Soto
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - C Kahatt
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | | | - C M Galmarini
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | | | - P Bohan
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - D Berton-Rigaud
- Department of Oncology, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes-Saint Herblain, France
| |
Collapse
|
20
|
Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol 2017; 20:89-96. [PMID: 29230692 PMCID: PMC5785607 DOI: 10.1007/s12094-017-1807-y] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 11/13/2017] [Indexed: 12/16/2022]
Abstract
Cancer of unknown primary site is a histologically confirmed cancer that manifests in advanced stage, with no identifiable primary site following standard diagnostic procedures. Patients are initially categorized based on the findings of the initial biopsy: adenocarcinoma, squamous-cell carcinoma, neuroendocrine carcinoma, and poorly differentiated carcinoma. Appropriate patient management requires understanding several clinical and pathological features that aid in identifying several subsets of patients with more responsive tumors.
Collapse
Affiliation(s)
- F Losa
- Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
| | - G Soler
- Hospital Durán i Reynals (ICO-L'Hospitalet), Barcelona, Spain
| | - A Casado
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - A Estival
- Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | - I Fernández
- Hospital Alvaro Cunqueiro-Complejo Hospitalario Universitario, Vigo, Spain
| | - S Giménez
- Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - F Longo
- Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - R Pazo-Cid
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - J Salgado
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Á Seguí
- Parc Taulí Sabadell, Hospital Universitari, Sabadell, Barcelona, Spain
| |
Collapse
|
21
|
Camacho AI, Hutchins B, Schwartz BF, Dorda BA, Casado A, Rey I. Description of a new genus and species of Bathynellidae (Crustacea: Bathynellacea) from Texas based on morphological and molecular characters. J NAT HIST 2017. [DOI: 10.1080/00222933.2017.1401680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A. I. Camacho
- Dpto. Biodiversidad y Biología Evolutiva, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain
| | - B. Hutchins
- Texas Parks and Wildlife Department, Austin, TX, USA
| | - B. F. Schwartz
- Department of Biology, Aquatic Station, Texas State University, San Marcos, TX USA
- Edwards Aquifer Research and Data Center, Texas State University, San Marcos, TX USA
| | - B. A. Dorda
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. Colecciones, Colección de Tejidos y ADN. Madrid, Spain
| | - A. Casado
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. Colecciones, Colección de Tejidos y ADN. Madrid, Spain
| | - I. Rey
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. Colecciones, Colección de Tejidos y ADN. Madrid, Spain
| |
Collapse
|
22
|
Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Laínez N, Martinez J, Redondo A, Romero I. SEOM Clinical Guideline in ovarian cancer (2016). Clin Transl Oncol 2016; 18:1206-1212. [PMID: 27905052 PMCID: PMC5138249 DOI: 10.1007/s12094-016-1588-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 11/17/2016] [Indexed: 12/01/2022]
Abstract
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer (OC) is the first cause of death due to gynecological cancer and the fifth cause of death for cancer in women in Spain. The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.
Collapse
Affiliation(s)
- A. Santaballa
- Servicio de Oncología Médica, Hospital Universitari I Politècnic La Fe, Avda de Fernando Abril Martorell, n. 106, 46026 Valencia, Spain
| | - P. Barretina
- Servicio de Oncología Médica, Institut Català d’Oncologia, Girona, Spain
| | - A. Casado
- Servicio de Oncología Médica, Hospital Clínico Universitario, San Carlos, Madrid, Spain
| | - Y. García
- Servicio de Oncología Médica, Corporació Sanitària Parc Taulí, Sabadell, Spain
| | | | - E. Guerra
- Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - N. Laínez
- Servicio de Oncología Médica, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - J. Martinez
- Servicio de Oncología Médica, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
| | - A. Redondo
- Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain
| | - I. Romero
- Servicio de Oncología Médica, Fundación Insituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
23
|
Romero I, Rubio M, Serrano R, Medina M, Minig L, Casado A, Coronado P, Martínez S, Orbegoso C, Fusté P, Alia EG, Sánchez-Martínez M, Rubio D, Santacana M, Ruiz M, Llombart-Cussac A, Matias-Guiu X, Poveda A. Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
van der Steen-Banasik E, Christiaens M, Shash E, Coens C, Casado A, Herrera F, Ottevanger P. Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 2016; 65:172-81. [DOI: 10.1016/j.ejca.2016.07.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 06/17/2016] [Accepted: 07/04/2016] [Indexed: 11/25/2022]
|
25
|
Camacho A, Brancelj A, Dorda B, Casado A, Rey I. New Parabathynellidae species in Africa: the first bathynellids from Chad and an assay of their phylogenetic position in the order Bathynellacea (Crustacea: Malacostraca) based on 18S sequences. J NAT HIST 2016. [DOI: 10.1080/00222933.2016.1210260] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- A.I. Camacho
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. Biodiversidad y Biología Evolutiva, C/ José Gutiérrez Abascal 2, 28006-Madrid, Spain
| | - A. Brancelj
- National Institute of Biology, Večna pot 111, 1000 Ljubljana, Slovenia
- School for Natural Sciences, Unversity of Nova Gorica, Vipavska c. 13, 5000 Nova Gorica, Slovenia
| | - B.A. Dorda
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. de Colecciones. Col. de Tejidos y ADN, C/ José Gutiérrez Abascal 2, 28006-MADRID (Spain)
| | - A. Casado
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. de Colecciones. Col. de Tejidos y ADN, C/ José Gutiérrez Abascal 2, 28006-MADRID (Spain)
| | - I. Rey
- Museo Nacional de Ciencias Naturales (CSIC), Dpto. de Colecciones. Col. de Tejidos y ADN, C/ José Gutiérrez Abascal 2, 28006-MADRID (Spain)
| |
Collapse
|
26
|
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, Altundag O, Amant F, van Leeuwenhoek A, Banerjee S, Bosse T, Casado A, de Agustín L, Cibula D, Colombo N, Creutzberg C, del Campo JM, Emons G, Goffin F, González-Martín A, Greggi S, Haie-Meder C, Katsaros D, Kesic V, Kurzeder C, Lax S, Lécuru F, Ledermann J, Levy T, Lorusso D, Mäenpää J, Marth C, Matias-Guiu X, Morice P, Nijman H, Nout R, Powell M, Querleu D, Mirza M, Reed N, Rodolakis A, Salvesen H, Sehouli J, Sessa C, Taylor A, Westermann A, Zeimet A. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2015; 27:16-41. [PMID: 26634381 DOI: 10.1093/annonc/mdv484] [Citation(s) in RCA: 685] [Impact Index Per Article: 76.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 10/05/2015] [Indexed: 12/27/2022] Open
Abstract
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.
Collapse
Affiliation(s)
- N Colombo
- Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy
| | - C Creutzberg
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - F Amant
- Department of Gynecological Oncology, University Hospital Leuven, Leuven, Belgium Center for Gynecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam
| | - T Bosse
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - A González-Martín
- Department of Medical Oncology, GEICO Cancer Center, Madrid Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | - J Ledermann
- Department of Oncology and Cancer Trials, UCL Cancer Institute, London, UK
| | - C Marth
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
| | - R Nout
- Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands
| | - D Querleu
- Department of Surgery, Institut Bergonié, Bordeaux, France Department of Gynecology and Obstetrics, McGill University Health Centre, Montreal, Canada
| | - M R Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - C Sessa
- Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Camacho A, Newell R, Crete Z, Dorda B, Casado A, Rey I. Northernmost discovery of Bathynellacea (Syncarida: Bathynellidae) with description of a new species ofPacificabathynellafrom Alaska (USA). J NAT HIST 2015. [DOI: 10.1080/00222933.2015.1083621] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Casado A, Sánchez-Gutiérrez V, Barrancos C, Albandea A. [Atypical presentation of lacrimal gland pleomorphic adenoma with necrotic foci]. Arch Soc Esp Oftalmol 2015; 90:432-434. [PMID: 25843695 DOI: 10.1016/j.oftal.2015.02.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 10/14/2014] [Accepted: 02/25/2015] [Indexed: 06/04/2023]
Abstract
CLINICAL CASE The case is presented of 48 year-old male complaining of a painful left upper eyelid and swelling of the lacrimal gland, with a suspicion of dacryoadenitis. Removal was decided after dacriops suspicion. Histopathology diagnosed a pleomorphic adenoma of the lacrimal gland, with areas of necrosis. DISCUSSION Lacrimal gland pleomorphic adenoma usually presents as a slowly progressive painless mass. However, painful presentation in this case might be related with necrotic foci found in the histopathological examination. Although not described in lacrimal glands, pleomorphic adenomas have already been reported in the major and minor salivary glands, and these patients also presented with a painful mass.
Collapse
Affiliation(s)
- A Casado
- Departamento de Oftalmología, Hospital Universitario Ramón y Cajal, Madrid, España.
| | - V Sánchez-Gutiérrez
- Departamento de Oftalmología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - C Barrancos
- Departamento de Oftalmología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - A Albandea
- Departamento de Oftalmología, Hospital Universitario Ramón y Cajal, Madrid, España
| |
Collapse
|
29
|
Bonanad S, De la Rubia J, Gironella M, Pérez Persona E, González B, Fernández Lago C, Arnan M, Zudaire M, Hernández Rivas JA, Soler A, Marrero C, Olivier C, Altés A, Valcárcel D, Hernández MT, Oiartzabal I, Fernández Ordoño R, Arnao M, Esquerra A, Sarrá J, González-Barca E, González J, Calvo X, Nomdedeu M, García Guiñón A, Ramírez Payer A, Casado A, López S, Durán M, Marcos M, Cruz-Jentoft AJ. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. J Geriatr Oncol 2015; 6:353-61. [PMID: 26139300 DOI: 10.1016/j.jgo.2015.03.003] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 03/24/2015] [Accepted: 03/31/2015] [Indexed: 12/27/2022]
Abstract
OBJECTIVES The purpose of this study was to develop a new brief, comprehensive geriatric assessment scale for older patients diagnosed with different hematological malignancies, the Geriatric Assessment in Hematology (GAH scale), and to determine its psychometric properties. MATERIALS AND METHODS The 30-item GAH scale was designed through a multi-step process to cover 8 relevant dimensions. This is an observational study conducted in 363 patients aged≥65years, newly diagnosed with different hematological malignancies (myelodysplasic syndrome/acute myeloblastic leukemia, multiple myeloma, or chronic lymphocytic leukemia), and treatment-naïve. The scale psychometric validation process included the analyses of feasibility, floor and ceiling effect, validity and reliability criteria. RESULTS Mean time taken to complete the GAH scale was 11.9±4.7min that improved through a learning-curve effect. Almost 90% of patients completed all items, and no floor or ceiling effects were identified. Criterion validity was supported by reasonable correlations between the GAH scale dimensions and three contrast variables (global health visual analogue scale, ECOG and Karnofsky), except for comorbidities. Factor analysis (supported by the scree plot) revealed nine factors that explained almost 60% of the total variance. Moderate internal consistency reliability was found (Cronbach's α: 0.610), and test-retest was excellent (ICC coefficients, 0.695-0.928). CONCLUSION Our study suggests that the GAH scale is a valid, internally reliable and a consistent tool to assess health status in older patients with different hematological malignancies. Future large studies should confirm whether the GAH scale may be a tool to improve clinical decision-making in older patients with hematological malignancies.
Collapse
Affiliation(s)
- S Bonanad
- Hematology Department, H. U. La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain.
| | - J De la Rubia
- Hematology Department, H. U. La Fe, Av. Fernando Abril Martorell, 106, 46026 Valencia, Spain
| | - M Gironella
- Hematology Department, H. U. Vall d'Hebrón, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - E Pérez Persona
- Hematology Department, H. U. Txagorritxu, c/ Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Álava, Spain
| | - B González
- Hematology Department, H. U. de Canarias, Ctra. Ofra, s/n, 38320 San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
| | - C Fernández Lago
- Hematology Department, C.H.U. A Coruña, As Xubias, 84, 15006, A Coruña, Spain
| | - M Arnan
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - M Zudaire
- Hematology Department, C.H. de Navarra, Av. Pío XII, 36, 31008 Pamplona, Navarra, Spain
| | - J A Hernández Rivas
- Hematology Department, H.U. Infanta Leonor, Avenida Gran Vía del Este, 80, 28031 Madrid, Spain
| | - A Soler
- Hematology Department, C.S. Parc Taulí, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain
| | - C Marrero
- Hematology Department, H. Ntra. Sra. de La Candelaria, Carretera del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain
| | - C Olivier
- Hematology Department, C.H. de Segovia, c/ de Miguel Servet, s/n, Segovia, Spain
| | - A Altés
- Hematology Department, H. Sant Joan de Déu, Passeig de Sant Joan de Déu, 2, 08950 Esplugues de Llobregat, Barcelona, Spain
| | - D Valcárcel
- Hematology Department, H. U. Vall d'Hebrón, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain
| | - M T Hernández
- Hematology Department, H. U. de Canarias, Ctra. Ofra, s/n, 38320 San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
| | - I Oiartzabal
- Hematology Department, H. U. Txagorritxu, c/ Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Álava, Spain
| | - R Fernández Ordoño
- Hematology Department, H.U. Infanta Leonor, Avenida Gran Vía del Este, 80, 28031 Madrid, Spain
| | - M Arnao
- Hematology Department, H.U. de La Ribera, Carretera Corbera, km 1, 46600 Alzira, Valencia, Spain
| | - A Esquerra
- Hematology Department, C.S. Parc Taulí, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain
| | - J Sarrá
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - E González-Barca
- Hematology Department, Catalan Institute of Oncology, IDIBELL, Hospital Duran i Reynals, Avinguda Granvia de l'Hospitalet, 199-203 08908 l'Hospitalet de Llobregat, Barcelona, Spain
| | - J González
- Hematology Department, H.U. Virgen del Rocío, Avenida Manuel Siurot, s/n, 41013 Sevilla, Spain
| | - X Calvo
- Hematology Department, Hospital Clínic de Barcelona, Carrer Villarroel, 170, 08036 Barcelona, Spain
| | - M Nomdedeu
- Hematology Department, Hospital Clínic de Barcelona, Carrer Villarroel, 170, 08036 Barcelona, Spain
| | - A García Guiñón
- Hematology Department, H.U. Arnau de Vilanova, Avenida Alcalde Rovira Roure, 80, 25198 Lleida, Spain
| | - A Ramírez Payer
- Hematology Department, H.U. Central de Asturias, Calle Carretera de Rubín, s/n, 33011 Oviedo, Spain
| | - A Casado
- U. Autónoma de Madrid, Dynamic Science S.L., c/Azcona, 31, 28028 Madrid, Spain
| | - S López
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - M Durán
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - M Marcos
- Celgene S.L.U., Paseo de Recoletos, 37, 28004 Madrid, Spain
| | - A J Cruz-Jentoft
- Geriatric Department, H.U. Ramón y Cajal, Ctra. de Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | | |
Collapse
|
30
|
Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur J Cancer 2014; 50:2408-16. [PMID: 25037684 DOI: 10.1016/j.ejca.2014.06.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Revised: 06/10/2014] [Accepted: 06/13/2014] [Indexed: 01/29/2023]
Abstract
AIM To evaluate the tolerability, pharmacokinetics and tumour response of first-line trebananib plus paclitaxel and carboplatin followed by trebananib maintenance in high-risk or advanced ovarian cancer. METHODS In this open-label phase 1b study, patients received intravenous (IV) trebananib 15 mg/kg administered weekly (QW) plus paclitaxel 175 mg/m(2) once every 3 weeks (Q3W) and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months. End-points were dose-limiting toxicities (DLTs; primary); treatment-emergent adverse events (AEs), anti-trebananib antibodies, pharmacokinetics and tumour response (secondary). RESULTS Twenty seven patients (interval debulking surgery [IDS], n=13) were enrolled. No DLTs occurred. During the combination therapy phase, AEs (>50%) in patients with IDS were nausea, diarrhoea, fatigue, decreased appetite and thrombocytopenia. In patients with primary debulking surgery (PDS), they were nausea, diarrhoea, fatigue and localised oedema. Grade 4 AEs were neutropenia (IDS, PDS; all n=3) and thrombocytopenia (IDS, PDS; all n=1). No deaths occurred. Toxicity results pertaining to trebananib maintenance were immature. The treatment combination did not markedly affect the pharmacokinetics across agents. In patients with IDS (n=14 after one patient was reassigned from PDS to IDS), 12 patients had a partial response (PR), two patients had stable disease. In patients with PDS (n=4), three patients had a complete response, one patient had a PR. CONCLUSIONS In women with ovarian cancer receiving IDS or PDS, IV trebananib 15 mg/kg QW plus paclitaxel and carboplatin appears tolerable. Results suggest that the treatment combination followed by trebananib 15 mg/kg monotherapy is associated with antitumour activity.
Collapse
Affiliation(s)
- I Vergote
- University Hospitals-KU Leuven, Leuven Cancer Institute, Department of Obstetrics and Gynecology, Herestraat 49, B-3000 Leuven, Belgium.
| | - A Oaknin
- Vall d'Hebron University Hospital, Medical Oncology Department, and Vall d'Hebron Institute of Oncology (VHIO), Head, Neck, and Gynecological Tumors Group, P. Vall d'Hebron 119-129, Barcelona 08035, Spain.
| | - J-F Baurain
- Université Catholique de Louvain, Centre du Cancer, Service d'Oncologie Médicale des Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, Bruxelles 1200, Belgium.
| | - S Ananda
- Royal Women's Hospital, Oncology Unit, 20 Flemington Road, Parkville 3052, VIC, Australia.
| | - S Wong
- Western Hospital, Department of Medical Oncology, Oncology Research Level 2 South, Gordon Street, Footscray 3011, VIC, Australia.
| | - X Su
- Amgen Inc., Department of Biostatistics, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
| | - B Wu
- Amgen Inc., Department of Pharmacokinetics and Drug Metabolism, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
| | - Z Zhong
- Amgen Inc., Department of Clinical Immunology and Biological Sample Management, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
| | - D Warner
- Amgen Inc., Department of Clinical Development, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.
| | - A Casado
- Hospital Universitario Clínico San Carlos, Servicio de Oncologia Medica, Calle del Professor Martín Lagos s/n, Madrid 28040, Spain.
| |
Collapse
|
31
|
Vergote I, Benzaquen AO, Baurain J, Ananda S, Wong S, Yang X, Wu B, Zhong Z, Puhlmann M, Casado A. A Phase 1b Study of AMG 386 Plus Paclitaxel and Carboplatin in Ovarian Cancer Patients Undergoing Primary or Interval Debulking Surgery. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33578-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
32
|
Penninckx B, Van de Voorde WM, Casado A, Reed N, Moulin C, Karrasch M. A systemic review of toxic death in clinical oncology trials: an Achilles' heel in safety reporting revisited. Br J Cancer 2012; 107:1-6. [PMID: 22677904 PMCID: PMC3389431 DOI: 10.1038/bjc.2012.252] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2012] [Revised: 05/04/2012] [Accepted: 05/11/2012] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Toxic death is defined as study treatment-related mortality and as such is considered as an iatrogenic death. This belongs to unnatural death where an autopsy is advised. Until now, conventional autopsy is the gold standard to discriminate between pre- and post-mortem discrepancies. METHODS The consequences of lack of systematically performing an autopsy will be explored in the setting of oncological clinical trials. RESULTS During more than one decade, 6428 Serious Adverse Events have been registered in the EORTC Safety database on a total of 34 734 subjects. The number of deaths were 764 (mortality rate of 2.2%) whereof 255 (rate of 0.7%) toxic deaths. In 89.8% of these toxic deaths, no autopsy has been done; in 25.1% (64 cases) an inconsistent cause of death was found based on studying of the medical narrative. The autopsy rate was only 10.2% (26 out of 255) and, in 46.2% of the performed autopsies, there was a clinical pathological discrepancy. CONCLUSION When no autopsy is performed, there is a high risk for a wrong diagnosis in case of suspected toxic death. The high discrepancy rate, possibly due to a low autopsy rate, shows that toxic death is an Achilles' heel in iatrogenic mortality.
Collapse
Affiliation(s)
- B Penninckx
- Medical Department, EORTC Headquarters, E. Mounierlaan 83/11, 1200 Brussels, Belgium.
| | | | | | | | | | | |
Collapse
|
33
|
Rodrigues J, Casado A, Duarte A, Santos C, Duarte A, Fernandez-Llimos F. Potential hospital pharmacists' interventions in antibacterial stewardship. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000074.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
34
|
Rodrigues J, Casado A, Duarte A, Santos C, Duarte A, Fernandez-Llimos F. Utility of defined daily dose system for identification of antibacterial potentially inappropriate prescribed doses. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000074.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
35
|
Rodrigues JFC, Duarte A, Palos C, Casado A, Santos C, Fernandez-Llimos F. Quality of surgical antibiotic prophylaxis using E-prescrption conditioning. BMC Proc 2011. [PMCID: PMC3239457 DOI: 10.1186/1753-6561-5-s6-o44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 2011; 55:680-687. [PMID: 21150863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM The aim of this study was to evaluate the utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in monitoring response in refractory GIST. METHODS This multicenter study prospectively evaluated 21 patients with locally advanced and/or metastatic GIST refractory to with high-dose imatinib (800 mg/day) treated with doxorubicin 15-20 mg/m2/weekly for 4 cycles, followed by imatinib maintenance (400 mg/day). CT and FDG-PET were performed at baseline and after completion of therapy. RESULTS Mean baseline tumor size on CT was 5.9 cm. Median progression-free survival (PFS) was 219 days (range 62-1108). Three out of 21 patients (14%) had partial responses (PR) under RECIST criteria, 12 patients (57%) remained stable (SD) and 6 showed progression (PD) of the disease during treatment (29%). Six patients had PR by FDG-PET, 15 showed SD (n=9) or PD (n=6) based on EORTC criteria. Patients with a PFS <6 mo showed a significantly higher ∑SUVmax at baseline (26.04±13.4) than those with PFS≥6 mo (9.82±5.0) (P<0.05). A correlation was found between PET response and PFS: PR 14±6.1 mo, SD 5.5±0.8 mo and PD 3.5±4.1 mo (P<0.05). A residual SUVmax <5 after treatment correlated with improved PFS (314±315 days vs 131±91 days) (P<0.01). Survival curves showed a significant association between PET response and PFS (P<0.05). Patients with wild-type genotype KIT (KIT-WT) showed a significantly lower baseline SUVmax (5.36±1.4) than non-WT KIT (8.40±3.6) (P<0.05). CONCLUSION FDG-PET is useful in assessing response of GIST refractory to imatinib and correlates with the presence of KIT-WT. Baseline ∑SUVmax can predict response to treatment in this series.
Collapse
Affiliation(s)
- D Fuster
- Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 2011; 9:127-32. [PMID: 18521419 PMCID: PMC2395634 DOI: 10.1080/13577140500287024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2005] [Revised: 07/05/2005] [Accepted: 07/22/2005] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR. PATIENTS AND METHODS Patients with measurable and progressive STS received PLD at 35 mg/(2) every 3 weeks. Quality of life before and during treatment was assessed with EORTC QLQ-C30. RESULTS Twenty-eight patients, 22 DXR-pretreated, were given 140 cycles (median 3, range 1-18). Activity in 27 patients (5 GIST): one complete and one partial remission (both non-GIST and without prior DXR), 12 stabilizations and 13 progressions (response rate 7.4%, 95% CI: 0-17%). Grade 3 toxicity: palmar-plantar erythrodysesthesia (19% of patients), stomatitis (4%) or cutaneous (4%). Neutropenia grade>/=3 was detected in 16% of patients. Median relative dose intensity was 95%. Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months. QLQ-C30 at baseline and at weeks 6-11 in 23 and 13 patients, respectively, showed good reliability and validity. Quality of life did not seem to worsen during therapy. CONCLUSIONS PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression-free rate figures support the use of this agent in patients who have not progressed under a DXR-containing regimen. The toxicity observed was comparable to that of other PLD schedules.
Collapse
Affiliation(s)
- A Poveda
- Instituto Valenciano de Oncología Valencia Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
López-Pousa A, Martín J, Montalar J, de las Peñas R, García del Muro J, Cruz J, Maurel J, Escudero P, Casado A, Buesa JM. Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 2011; 2006:26986. [PMID: 17251655 PMCID: PMC1698138 DOI: 10.1155/srcm/2006/26986] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2005] [Revised: 05/22/2006] [Accepted: 06/06/2006] [Indexed: 11/24/2022] Open
Abstract
Background. To explore the tolerance and the activity of
high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50
mg/m2 every 4 weeks in patients with soft tissue
sarcomas. Methods. DXR was given IV bolus and IFOS by
continuous infusion at 2 g/m2/day. Initial IFOS dose (12
g/m2) was adjusted to 10, 13, or 14 g/m2
according to toxicity. Results. Seventy patients received
277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose
increased, 30% decreased, and 48% delivered at 12
g/m2. Toxicity grade 4 occurred on granulocytes (67%
of patients) or platelets (19%), 54% had febrile
neutropenia, 31% grade 3/4 asthenia, and 26% abandoned the
study due to toxicity. Three toxic deaths occurred. In 57 non-GIST
patients objective activity was 45.6% (95% CI, 32 to
58%). Conclusion. At least 4 cycles were tolerated by
71% of patients, most receiving DXR 50 mg/m2 plus
IFOS 10–12 g/m2, with substantial toxicity.
Collapse
Affiliation(s)
- A. López-Pousa
- Medical Oncology Department, Hospital Sant Pau, 08025 Barcelona, Spain
| | - J. Martín
- Medical Oncology Department, Hospital Son Dureta, 07014 Palma de Mallorca, Spain
| | - J. Montalar
- Medical Oncology Department, Hospital Clínico La Fe, 46009 Valencia, Spain
| | - R. de las Peñas
- Medical Oncology Department, Hospital Provincial, 12002 Castellón, Spain
| | - J. García del Muro
- Medical Oncology Department, Instituto Catalán de Oncología, 08907 Barcelona, Spain
| | - J. Cruz
- Medical Oncology Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain
| | - J. Maurel
- Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain
| | - P. Escudero
- Medical Oncology Department, Hospital Clínico, 50009 Zaragoza, Spain
| | - A. Casado
- Medical Oncology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain
| | - J. M. Buesa
- Medical Oncology Department, Hospital Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, Spain
- *J. M. Buesa: ,
| |
Collapse
|
39
|
Pfisterer J, Berek JS, Casado A, Cwiertka K, Pinter T, Pluzanska A, Pujade-Lauraine E, Scambia G, Vermorken JB, Simonelli C, Bertolotti M, Capriati A, Sabbatini P. Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba5002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA5002 Background: Abagovomab, a murine monoclonal anti-idiotypic antibody directed against CA125, has been shown to induce an active immune response against CA125 tumor-associated antigen in advanced ovarian cancer patients. Methods: Abagovomab (A) has been tested in a randomized (2:1) double-blind, placebo (P) controlled, multicenter phase II/III trial in patients with FIGO stage III/IV ovarian cancer after complete response to platinum-taxane first-line chemotherapy. A (2 mg/1 ml) or P was given subcutaneously every 2 weeks for 6 weeks (induction phase); then every 4 weeks (maintenance phase) until recurrence, or up to 21 months after the last patient had been randomized. Primary endpoint is progression-free survival (PFS); secondary endpoints are OS and immunological response. An estimated 870 patients, with a mean follow-up of 18 months, were needed to observe at least 535 recurrences, which provides a power >90% in rejecting the null hypothesis of equality between A and P on PFS according to a hazard ratio (HR) of 1.33, in which median P PFS time is 18 months, significance level (a) 5% (two-sided), and the overall dropout rate 10%. Primary analysis was run on PFS in the ITT population. The design included a prospective stratification in randomization for the following prognostic factors: FIGO stage (III-IV); tumor size after debulking (residual tumor <1 cm, >1 cm); and CA125 serum level after the third cycle (<35 U/ml, >35 U/ml). The Cox proportional hazards model was used for adjusting the primary analysis. Results: 888 patients were enrolled by December 2008, 593 in A arm and 295 in P arm. The median follow-up was 28.1 months and the mean number treatment administrations was 18. Baseline characteristics were balanced between arms. Overall tolerability profile was consistent with previous A studies. Median (95% CI) PFS was 13.24 (10.612-13.602) months for A arm and 13.21 (10.612-16.000) months for P arm; HR=1.099 (0.919-1.315); p=0.301. Conclusions: Treatment with A did not translate into a prolonged PFS.
Collapse
Affiliation(s)
- J. Pfisterer
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - J. S. Berek
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - A. Casado
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - K. Cwiertka
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - T. Pinter
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - A. Pluzanska
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - E. Pujade-Lauraine
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - G. Scambia
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - J. B. Vermorken
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - C. Simonelli
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - M. Bertolotti
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - A. Capriati
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | - P. Sabbatini
- Klinikum Solingen, Solingen, Germany; Stanford Cancer Center, Stanford, CA; Hospital Universitario San Carlos, Madrid, Spain; Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; Petz Aladar Megyei Oktato Korhaz Onkoradiologia, Gyõr, Hungary; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Department of Medical Oncology, Hopital Hotel-Dieu, Paris, France; Catholic University, Rome, Italy; Antwerp University Hospital, Edegem, Belgium; Menarini Ricerche, Firenze, Italy; Memorial Sloan-Kettering Cancer
| | | |
Collapse
|
40
|
Ojeda B, Casado A, Tibau A, Redondo A, Beltran M, Garcia-Martinez E, Santaballa A, Pardo B, Lianes P, Bover I, Garcia-Donas J, Churruca CM, Cueva JF, Sanchez-Heras AB, Gordon-Santiago MM, Arcusa Lanza A, Lopez-Rodriguez A, Caballero C, Ortega-Izquierdo ME, González-Martín A. Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz-Mateu M, Caronia D, Carrasco EM, Garcia Saenz JÁ, Casado A, Chacón I, Hernando B, Ruiz-Borrego M, Gonzalez-Neira A. Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009−05 study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Rubió J, Martinez-Trufero J, Lopez-Pousa A, Garcia del Muro X, Fra J, Redondo A, Lainez N, Poveda A, Casado A, Valverde CM, De Juan A, Sevilla I, Andres R, Cruz J, Safont MJ, Martin Broto J, Garcia-Albeniz X, Maurel J. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Pfisterer J, Berek JS, Casado A, Cwiertka K, Pinter T, Pluzanska A, Pujade-Lauraine E, Scambia G, Vermorken JB, Simonelli C, Bertolotti M, Capriati A, Sabbatini P. Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba5002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Martin M, Romero A, Cheang MCU, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011; 128:127-36. [PMID: 21465170 DOI: 10.1007/s10549-011-1461-y] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2011] [Accepted: 03/15/2011] [Indexed: 12/24/2022]
Abstract
UNLABELLED Taxanes and anthracyclines improve the outcome of early breast cancer, although the benefit is limited to a small proportion of patients and are toxic. We prospectively looked for predictors of response to these drugs. EXPERIMENTAL DESIGN Four cycles of doxorubicin (75 mg/m²) or docetaxel (100 mg/m²) were compared as presurgical chemotherapy for breast cancer. Biomarkers were determined by immunohistochemistry and fluorescent in situ hybridization using prechemotherapy core biopsies. Tumors were also classified into one of the molecular intrinsic subtypes using an immunohistochemical panel of five biomarkers and genomic profiles. Single genes and intrinsic subtypes were correlated with response to doxorubicin versus docetaxel. Among the 204 evaluable patients, significant predictors of sensitivity in multivariate analysis were low topo2a expression and ER-negative status for doxorubicin and small tumor size and ER-negative status for docetaxel. Predictors of resistance in multivariate analysis were triple-negative status (ER/PgR/HER2 negative by IHC/FISH) for doxorubicin, and high TNM stage for docetaxel. Triple-negative tumors were associated with topo2a overexpression more than the other subtypes. In 94 patients with gene expression profiles, docetaxel was superior to doxorubicin in the basal-like subtype (good pathological response rate - PCR + class I of 56 vs. 0%; P = 0.034); no significant differences were observed in the other subtypes when comparing these two drugs. Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences were seen in the remaining intrinsic subtypes.
Collapse
Affiliation(s)
- M Martin
- Servicio de Oncología Médica, Hospital Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Martín M, Sánchez-Rovira P, Muñoz M, Baena-Cañada JM, Mel JR, Margeli M, Ramos M, Martínez E, García-Saenz JA, Casado A, Jaén AM, González-Farré X, Escudero MJ, Rodriguez-Martin C, Carrasco E. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011; 22:2591-2596. [PMID: 21421542 DOI: 10.1093/annonc/mdr024] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In order to determine the feasibility of substituting pegylated liposomal doxorubicin (PLD) for doxorubicin in combination with cyclophosphamide and trastuzumab as adjuvant therapy, we conducted a phase II study of the combination as first-line therapy in human epidermal growth factor receptor 2 (HER2) overexpressing metastatic breast cancer (MBC). METHODS PLD 50 mg/m(2) and cyclophosphamide 600 mg/m(2) were administered every 4 weeks for six cycles; trastuzumab (4 mg/kg loading dose, then 2 mg/kg) was administered weekly for 24 weeks. The primary end point was objective response rate (ORR), and the secondary end points included time to progression (TTP), overall survival (OS), and safety. RESULTS Among the 48 evaluable patients, ORR was 68.8% [95% confidence interval (CI) 55.69% to 81.91%], with 6 patients (12.5%) achieving a complete response and 27 (56.2%) a partial response. The median TTP was 12 months (95% CI 9-15.1 months), and the median OS was 34.2 months (95% CI 27.2-41.2 months). Febrile neutropenia was seen in three patients, grade 3 hand-foot syndrome in 29.2% of patients, and grade 3-4 mucositis in 22.9% of patients. Symptomatic congestive heart failure was not observed, and 16.7% of patients experienced grade 2 asymptomatic left ventricular systolic dysfunction. CONCLUSION The combination of PLD-cyclophosphamide-concurrent trastuzumab is a feasible, safe, and effective first-line regimen for HER2-overexpressing MBC.
Collapse
Affiliation(s)
- M Martín
- Medical Oncology Department, Hospital Clínico San Carlos, Madrid.
| | - P Sánchez-Rovira
- Medical Oncology Departmanet, Complejo Hospitalario de Jaén, Jaén
| | - M Muñoz
- Medical Oncology Department, Hospital Clinic i Provincial, Barcelona
| | | | - J R Mel
- Medical Oncology Department, Hospital Xeral Calde, Lugo
| | - M Margeli
- Medical Oncology Department, Hospital Germans Trias y Pujol, Badalona
| | - M Ramos
- Medical Oncology Department, Centro Oncologico de Galicia, A Coruña
| | - E Martínez
- Medical Oncology Department, Hospital Provincial de Castellón, Castellón
| | - J A García-Saenz
- Medical Oncology Department, Hospital Clínico San Carlos, Madrid
| | - A Casado
- Medical Oncology Department, Hospital Clínico San Carlos, Madrid
| | - A M Jaén
- Medical Oncology Departmanet, Complejo Hospitalario de Jaén, Jaén
| | - X González-Farré
- Medical Oncology Department, Hospital Clinic i Provincial, Barcelona
| | | | | | | | | |
Collapse
|
46
|
Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel. J Natl Cancer Inst 2010; 102:1547-1556. [DOI: 10.1093/jnci/djq362] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
47
|
Sabbatini P, Berek JS, Casado A, Cwiertka K, Pinter T, Pluzanska A, Scambia G, Pujade-Lauraine E, Vermorken JB, Pfisterer J. Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5036] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010; 21:1552-1557. [PMID: 20231303 DOI: 10.1093/annonc/mdq047] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. PATIENTS AND METHODS A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0-4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen-Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. RESULTS Multivariate analyses revealed that M-L/AFIP [relative risk (RR) 11.45, confidence interval (CI) 4.40-29.76, for the high-risk subgroup and RR 5.97, CI 2.09-17.06, for the intermediate subgroup] and critical deletions (RR 3.05, CI 1.59-5.85) were independent prognostic factors for RFS for the first 4 years and for the entire follow-up period. Beyond 4 years, the high-risk M-L/AFIP subgroup (RR 8.12, CI 1.48-44.4) and NDTM (RR 6.42, CI 1.17-35.12) were independent prognostic factors for RFS. The median follow-up was 84 months. CONCLUSION Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients.
Collapse
Affiliation(s)
- J Martin-Broto
- Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca.
| | - A Gutierrez
- Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca
| | | | - J A Lopez-Guerrero
- Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia
| | | | - L M de Sande
- Department of Oncology, Complejo Hospitalario de León, Leon
| | - N Lainez
- Department of Oncology, Hospital Virgen del Camino, Pamplona
| | - J Maurel
- Department of Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas, Barcelona
| | - A De Juan
- Oncology Department, Hospital de Valdecilla, Santander
| | - F Losa
- Department of Oncology, Hospital General, Hospitalet de Llobregat
| | - R Andres
- Department of Oncology, Hospital Clínico Lozano Blesa, Zaragoza
| | - A Casado
- Department of Oncology, Hospital Universitario San Carlos, Madrid
| | - P G Tejido
- Department of Oncology, Hospital San Pedro, Logroño
| | - R Blanco
- Department of Oncology, Hospital Mutua de Terrassa, Terrassa
| | - J Carles
- Department of Oncology, Hospital del Mar, Barcelona
| | - J Bellmunt
- Department of Oncology, Hospital Vall d'Hebron, Barcelona
| | | | - R Ramos
- Department of Pathology, Hospital Universitario Son Dureta, Palma de Mallorca
| | - J Martinez-Serra
- Laboratory of Molecular Biology, Hospital Universitario Son Dureta, Palma de Mallorca
| | | | - A Poveda
- Department of Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
49
|
Anta Tejado L, Molina-Ruiz R, Tajima-Pozo K, Yus M, Casado A, Carrasco-Perera J, Diaz-Marsá M. PW01-142 - Abnormal amygdala response in women with eating disorder: a fMRI study. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)71541-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
López-Tarruella S, López-Tarruella S, Puente J, Lluch A, Climent M, Pastor M, Alba E, Mayordomo J, Díaz-Rubio E, Casado A, Casado A, Cano S, Martín M, Martín M. Impact on Survival of Primary Tumor Resection in Women with Metastatic Breast Cancer at Initial Diagnosis. The Alamo Project. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent medical and scientific reports suggest that surgery of the primary tumor (PT) could be taken into account, although far from the current standard of care, in metastatic breast cancer (MBC) patients. The mechanistic basis for these findings stem from crosstalk between the PT and metastatic foci, immunosuppressive effects, and/or the avoidance of metastatic re-seeding from the primary source. We have focused on implementing surgical excision of the PT in certain settings and tumor types in order to ascertain whether this aggressive treatment modality can be justified in a classic palliative setting. Methods: The ALAMO Project (A) is a retrospective analysis of patients (pts) diagnosed with BC between 1990 and 1997 across 43 GEICAM hospitals. Patterns of BC presentation (tumor and host characteristics), treatment and survival were recorded in 2 cohorts, AI (1990-93, 4532 pts, closed by 2000) and AII (1994-97, 10849 pts, closed by 2003). Only MBC pts at first diagnosis were included, excluding those with secondary tumors, without a minimum of 2 months follow-up at the same institution, and without complete information regarding their PT surgery. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Results: 6.12% of the ALAMO database pts were initially diagnosed with MBC (605 fulfilled the present analysis criteria), with a medium age of 61.6 years (yrs). 54.2% had single-organ metastasis, anatomically distributed in skin/soft tissue (18.8%), bone (35.9%), lung (9.8%), and other viscera (35.5%). 26.3% of pts had surgery of the PT (83.7% of them radical procedures, 73.3% of them axillary dissected and 5.6% received radiotherapy). Chemotherapy (30.7%), endocrine therapy (23.1%) or both (41.7%) were the systemic approaches, and 4.5% received supportive care. Women in the surgery (S) group (159 pts) were younger, with skin/soft tissue or bone metastasis and oligometastatic disease. 5-yr overall survival (OS) was 18.84%, 2.94 yrs median OS in the S-group versus 1.83 yrs in the nS-group (p<0.001). A stratified analysis by organ showed relevant effects of surgery for pts with skin/soft tissue metastasis, 4.52 yrs versus 1.77 yrs median OS in the S and nS arms respectively. The multi-adjusted HR for surgery in this subgroup was 0.30 (p<0.001), which was not significantly modified considering a propensity score (PS) factor (HR 0.29, p<0.001). Surgery (p<0.001), systemic treatment (p<0.001), and the interaction between surgery and metastatic location (p<0.004) were included in the multivariate predictive model of survival for the whole series. Discussion: Local surgery of the PT is associated with an increase in OS for pts with skin/soft tissue metastasis and is maintained in multi-adjusted models. These analyses suggest that loco-regional control of the PT should be considered for the treatment of advanced disease in selected patients, but must be further investigated in randomized controlled trials in MBC at first diagnosis.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3104.
Collapse
Affiliation(s)
| | | | - J. Puente
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - A. Lluch
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Climent
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Pastor
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - E. Alba
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - J. Mayordomo
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | | | - A. Casado
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - A. Casado
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - S. Cano
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - M. Martín
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Martín
- 2Hospital Clínico San Carlos, Madrid, Spain
| |
Collapse
|